NPFD vs FULC Comparison

Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.